Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of elafibranor in adults with primary sclerosing cholangitis
CTR20263519Phase 3Active
- Sponsor
- Ipsen
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elafibranor in Primary Sclerosing Cholangitis (PSC), sponsored by Ipsen. Started Sep 2026; status: active.
02
Drugs
elafibranor
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on CTR20263519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263519.